Compare AIRE & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | GNTA |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.7M | 41.7M |
| IPO Year | N/A | 2021 |
| Metric | AIRE | GNTA |
|---|---|---|
| Price | $0.44 | $1.41 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 123.8K |
| Earning Date | 11-12-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,149,567.00 | N/A |
| Revenue This Year | $411.48 | N/A |
| Revenue Next Year | $141.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 994.18 | N/A |
| 52 Week Low | $0.14 | $1.30 |
| 52 Week High | $4.49 | $10.00 |
| Indicator | AIRE | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 32.09 |
| Support Level | $0.51 | $1.80 |
| Resistance Level | $0.53 | $1.77 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 2.60 | 11.96 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.